Please login to the form below

Not currently logged in
Email:
Password:

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.

At GW he will assume in the newly-created role of VP, clinical research, where he will lead clinical development, medical affairs, and regulatory activities related to the company's work in epilepsy, pain and other diseases.

GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis in Canada and the European Union in 2010. It is also in clinical trials for other indications, including cancer pain.

"This is an exciting time to be joining GW, with a number of important products currently under development for patients in the US including Sativex and Epidiolex,” said Dr Sommerville.

8th May 2014

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...